Halozyme Therapeutics (DE:RV7)
FRANKFURT:RV7

Halozyme Financial Statements

0 Followers

Halozyme Financial Overview

Halozyme's market cap is currently ―. The company's EPS TTM is €; its P/E ratio is ―; Halozyme is scheduled to report earnings on February 21, 2023, and the estimated EPS forecast is €0.26. See an overview of income statement, balance sheet, and cash flow financials.
Sep 22Jun 22Mar 22Dec 21Sep 21
Income Statement
Total Revenue$ 208.98M$ 152.37M$ 117.28M$ 102.00M$ 115.83M
Gross Profit$ 161.66M$ 118.42M$ 101.36M$ 80.42M$ 97.24M
EBIT$ 81.22M$ 33.12M$ 76.17M$ 56.87M$ 75.86M
EBITDA$ 110.42M$ 45.66M$ 76.95M$ 57.64M$ 76.61M
Net Income Common Stockholders$ 61.63M$ 22.68M$ 60.11M$ 66.77M$ 216.59M
Balance Sheet
Cash, Cash Equivalents and Short-Term Investments$ 265.58M$ 209.36M$ 786.14M$ 740.92M$ 815.92M
Total Assets$ 1.86B$ 1.78B$ 1.16B$ 1.10B$ 1.19B
Total Debt$ 1.50B$ 1.25B$ 877.64M$ 876.67M$ 875.71M
Net Debt$ 1.24B$ 1.04B$ 91.50M$ 135.75M$ 59.78M
Total Liabilities$ 1.77B$ 1.49B$ 901.99M$ 907.48M$ 903.75M
Stockholders Equity$ 96.99M$ 293.17M$ 260.26M$ 196.95M$ 281.67M
Cash Flow
Free Cash Flow$ 68.63M$ 39.26M$ 47.31M$ 82.36M$ 121.24M
Operating Cash Flow$ 69.64M$ 40.23M$ 47.80M$ 82.52M$ 121.74M
Investing Cash Flow$ -1.01M$ -434.95M$ -49.30M$ -299.47M$ -16.95M
Financing Cash Flow$ -12.40M$ 367.82M$ 624.00K$ -156.01M$ -60.07M
Currency in USD

Halozyme Earnings and Revenue History


Halozyme Debt to Assets


Halozyme Cash Flow


Halozyme Forecast EPS vs Actual EPS


What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis